Thelansis

  Adult polyglucosan body disease (APBD) is a rare genetic disorder characterized by a deficiency of the glycogen-branching enzyme, resulting in the accumulation of polyglucosan bodies in muscle, nerve and various other tissues of the body. Polyglucosan bodies are composed of large, complex, sugar-based molecules. Approximately 200 affected individuals have been diagnosed with APBD worldwide. Thelansis’s “Adult Polyglucosan Body Disease (APBD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adult Polyglucosan Body Disease (APBD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Adult Polyglucosan Body Di...